These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31663869)

  • 21. Community Health Center 340B Program: A Qualitative Study of the Experiences of Patients with Diabetes.
    Wagner AA; Whitner JB; Williams AC; Hirt KL; Miracle TL; Valentino AS
    Innov Pharm; 2023; 14(3):. PubMed ID: 38487386
    [No Abstract]   [Full Text] [Related]  

  • 22. Income differences between locations of 340B entities and contract pharmacies.
    Masia N; Kuwonza F
    Am J Manag Care; 2023 Jun; 29(6):e184-e188. PubMed ID: 37341983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consequences of the 340B Drug Pricing Program.
    Desai S; McWilliams JM
    N Engl J Med; 2018 Feb; 378(6):539-548. PubMed ID: 29365282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growing pains. Insurers and PbMs want in on 340B savings.
    Lee J
    Mod Healthc; 2012 Mar; 42(11):10. PubMed ID: 22462315
    [No Abstract]   [Full Text] [Related]  

  • 25. 340B Participation and Safety Net Engagement Among Federally Qualified Health Centers.
    Watts E; McGlave C; Quinones N; Bruno JP; Nikpay S
    JAMA Health Forum; 2024 Oct; 5(10):e243360. PubMed ID: 39365605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in 340B Drug Pricing Program Contract Growth Among Retail Pharmacies From 2009 to 2022.
    Nikpay S; McGlave CC; Bruno JP; Yang H; Watts E
    JAMA Health Forum; 2023 Aug; 4(8):e232139. PubMed ID: 37540525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
    Mulligan K; Romley JA; Myerson R
    BMC Res Notes; 2021 Jun; 14(1):228. PubMed ID: 34082835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of the 340B Drug Pricing Program on Critical Access Hospitals: Evidence from Medicare Part B.
    Han D
    J Health Econ; 2023 May; 89():102754. PubMed ID: 37030057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementation of a $4 generic drug program in a 340B pharmacy.
    Bright DR; Adams AJ; Akala FO; Lengel AJ; Martin SJ; Powers MF
    Am J Health Syst Pharm; 2010 Jun; 67(11):929-31. PubMed ID: 20484217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
    Zeta LM
    Food Drug Law J; 2015; 70(4):481-99, i. PubMed ID: 26827389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule; further delay of effective date.
    Health Resources and Services Administration, HHS
    Fed Regist; 2017 May; 82(96):22893-5. PubMed ID: 28574239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addressing financial toxicity in cancer treatment-An opportunity for the 340B drug pricing program.
    Faraj KS; Caram MEV; Shahinian VB; Hollenbeck BK
    Cancer; 2024 Sep; 130(18):3077-3081. PubMed ID: 38804732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Commercial markups on pediatric oncology drugs at 340B pediatric hospitals.
    Liu ITT; Wang J; Sarpatwari A; Kesselheim AS; Feldman WB
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31158. PubMed ID: 38970222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Access To Oncology Services In Rural Areas: Influence Of The 340B Drug Pricing Program.
    Owsley KM; Bradley CJ
    Health Aff (Millwood); 2023 Jun; 42(6):785-794. PubMed ID: 37276477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tips for preparing for a 340B integrity audit.
    Wood W; Jorgenson J; Kelly W
    Healthc Financ Manage; 2012 Dec; 66(12):50-2. PubMed ID: 23252228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Balancing medicine prices and business sustainability: analyses of pharmacy costs, revenues and profit shed light on retail medicine mark-ups in rural Kyrgyzstan.
    Waning B; Maddix J; Soucy L
    BMC Health Serv Res; 2010 Jul; 10():205. PubMed ID: 20626904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics.
    Lin JK; Li P; Doshi JA; Desai SM
    JAMA Health Forum; 2022 Jun; 3(6):e221435. PubMed ID: 35977245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing provider knowledge of the federal 340B Drug Pricing Program in a federally qualified health center.
    De La Riva L; Gray E; Braden-Suchy N; Irwin AN
    Am J Health Syst Pharm; 2024 Oct; 81(21):e692-e699. PubMed ID: 38557600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer-Reviewed Literature.
    Levengood TW; Conti RM; Cahill S; Cole MB
    Milbank Q; 2024 Jun; 102(2):429-462. PubMed ID: 38282421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Discounted and Undiscounted Cash Prices for Cardiovascular Medications by Type of US Community Pharmacy.
    Hong M; Shcherbakova N
    J Gen Intern Med; 2021 Jan; 36(1):114-120. PubMed ID: 32885368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.